Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Financials
Key financial figures for Mirum Pharmaceuticals, Inc. Common Stock (Q3 2026).
Mirum reported Q3 2026 net product sales of $185.7 million, up from $133.0 million a year earlier, and raised 2026 net product sales guidance to $715 million to $720 million. Net product sales were $185.7 million versus $133.0 million in Q3 2025, and total revenue equals product sales in both periods. LIVMARLI net product sales were $133.4 million, 45% above Q3 2025, and Bile Acid Medicines (CHOLBAM, CHENODAL and CTEXLI) were $52.3 million, 28% above Q3 2025. Loss from operations was $59.7 million versus income from operations of $2.6 million a year earlier; operating expenses of $245.5 million included $13.5 million of non-recurring acquired in-process R&D, and R&D expense rose to $107.9 million from $43.0 million. On the outlook: 2026 net product sales guidance increased to $715 million to $720 million, from $680 million to $700 million in the Q2 2026 release. Figures are for Q3 2026, as Mirum Pharmaceuticals, Inc. reported them.
- Revenue
- $186M
- Net Income
- -$41M
- EPS
- $-0.62
- Total Assets
- $1.0B
- Operating Cash Flow
- -$4M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $186M | -$41M | -$0.62 | -32.17% | -$6M |
| Q2 FY2026 | $176M | -$67M | -$1.06 | -24.14% | -$274M |
| Q1 FY2026 | $160M | -$790M | -$13.43 | -39.51% | -$229M |
| Q4 FY2025 | $149M | -$6M | -$0.12 | -3.07% | $5M |
| Q3 FY2025 | $133M | $3M | $0.05 | 1.96% | $39M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $521M | -$23M | -$0.47 | -4.25% | $55M |
| FY2024 | $337M | -$88M | -$1.85 | -26% | $9M |
| FY2023 | $186M | -$163M | -$4.00 | -58.57% | -$91M |
Frequently asked questions
What was Mirum Pharmaceuticals, Inc.'s revenue last quarter?
Mirum Pharmaceuticals, Inc. reported revenue of $185.7 million for Q3 FY2026, up 39.6% from the same period a year earlier.
Is Mirum Pharmaceuticals, Inc. profitable?
Not in its most recent reported period. Mirum Pharmaceuticals, Inc. reported a net loss of $40.8 million for Q3 FY2026, a net margin of -21.95% on revenue.
How has Mirum Pharmaceuticals, Inc.'s margin trended?
Operating margin was -32.17% in Q3 FY2026, compared with 1.96% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Mirum Pharmaceuticals, Inc. generate?
Mirum Pharmaceuticals, Inc. generated free cash flow of -$5.6 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Mirum Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.